Compare AstraZeneca plc (AZN) vs eBay Inc (EBAY) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

EBAY trades at $107.71, down 3.81% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals but maintains strong fundamentals with 18.57% net margins and consistent earnings beats. Recent Q2 results exceeded expectations with 14% GMV growth, though insider selling and takeover uncertainty create near-term pressure.

EBAY offers solid fundamentals with improving revenue guidance and attractive valuation multiples, but faces significant event risk from the potential GameStop deal collapse. The 11% upside to consensus price target suggests moderate bullish sentiment, though investors should monitor partnership developments and Q3 earnings for directional clarity.